These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 31779978)

  • 21. Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia.
    Pei S; Pollyea DA; Gustafson A; Stevens BM; Minhajuddin M; Fu R; Riemondy KA; Gillen AE; Sheridan RM; Kim J; Costello JC; Amaya ML; Inguva A; Winters A; Ye H; Krug A; Jones CL; Adane B; Khan N; Ponder J; Schowinsky J; Abbott D; Hammes A; Myers JR; Ashton JM; Nemkov T; D'Alessandro A; Gutman JA; Ramsey HE; Savona MR; Smith CA; Jordan CT
    Cancer Discov; 2020 Apr; 10(4):536-551. PubMed ID: 31974170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Venetoclax in AML: Where We Are and Where We Are Headed.
    Pollyea DA
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S25-S26. PubMed ID: 32862856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Venetoclax: a new player in the treatment of children with high-risk myeloid malignancies?
    Masetti R; Baccelli F; Leardini D; Locatelli F
    Blood Adv; 2024 Jul; 8(13):3583-3595. PubMed ID: 38701350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Venetoclax combination therapy induces deep AML remission with eradication of leukemic stem cells and remodeling of clonal haematopoiesis.
    Vazquez R; Breal C; Zalmai L; Friedrich C; Almire C; Contejean A; Barreau S; Grignano E; Willems L; Deau-Fischer B; Franchi P; Vignon M; Decroocq J; Birsen R; Goldwirt L; Kaltenbach S; Couronne L; Fontenay M; Kosmider O; Bouscary D; Chapuis N
    Blood Cancer J; 2021 Mar; 11(3):62. PubMed ID: 33741892
    [No Abstract]   [Full Text] [Related]  

  • 25. Biomarkers of Response to Venetoclax Therapy in Acute Myeloid Leukemia.
    Rodríguez-Medina C; Stuckey R; Bilbao-Sieyro C; Gómez-Casares MT
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine.
    Tambe M; Unterberger S; Kriegbaum MC; Vänttinen I; Olgac EJ; Vähä-Koskela M; Kontro M; Wennerberg K; Heckman CA
    Cell Death Dis; 2024 Oct; 15(10):750. PubMed ID: 39414773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.
    Nechiporuk T; Kurtz SE; Nikolova O; Liu T; Jones CL; D'Alessandro A; Culp-Hill R; d'Almeida A; Joshi SK; Rosenberg M; Tognon CE; Danilov AV; Druker BJ; Chang BH; McWeeney SK; Tyner JW
    Cancer Discov; 2019 Jul; 9(7):910-925. PubMed ID: 31048320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
    Naqvi K; Konopleva M; Ravandi F
    Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Application of Bcl-2 inhibitor venetoclax in acute myeloid leukemia].
    Zhang Y; Jin J
    Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):438-440. PubMed ID: 34218592
    [No Abstract]   [Full Text] [Related]  

  • 30. Therapeutic development and current uses of BCL-2 inhibition.
    Roberts AW
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):1-9. PubMed ID: 33275682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center.
    Secilmis S; Sinan Dal M; Kizil Cakar M; Merdin A; Ahu Baysal N; Altuntas F
    J BUON; 2021; 26(5):2026-2032. PubMed ID: 34761613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells.
    Jones CL; Stevens BM; Pollyea DA; Culp-Hill R; Reisz JA; Nemkov T; Gehrke S; Gamboni F; Krug A; Winters A; Pei S; Gustafson A; Ye H; Inguva A; Amaya M; Minhajuddin M; Abbott D; Becker MW; DeGregori J; Smith CA; D'Alessandro A; Jordan CT
    Cell Stem Cell; 2020 Nov; 27(5):748-764.e4. PubMed ID: 32822582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
    Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y
    Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real world results of venetoclax combined with hypomethylating agents in relapsed/refractory AML.
    Ucar MA; Ozet G; Koyuncu MB; Sonmez M; Akidan O; Ayli M; Yildirim M; Pehlivan M; Akkurd DM; Sahin H; Guvenc B; Okan V; Tiftik EN; Akdeniz A; Dincyurek HD; Gunes AK; Dagdas S; Acar HI; Ucar HK; Tombak A
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(21):6557-6565. PubMed ID: 34787859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Double remission of simultaneously occurring secondary AML and CLL by venetoclax monotherapy.
    Niscola P; Noguera NI; Catalano G; Cupelli L; Fratoni S; Giovannini M; Mazzone C; Neri B; Scaramucci L; Trawinska MM; de Fabritiis P; Abruzzese E
    Acta Oncol; 2019 Jun; 58(6):888-890. PubMed ID: 30848978
    [No Abstract]   [Full Text] [Related]  

  • 36. Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice.
    Apel A; Moshe Y; Ofran Y; Gural A; Wolach O; Ganzel C; Canaani J; Zektser M; Duek A; Stemer G; Hellman I; Basood M; Frisch A; Leibovitch C; Koren-Michowitz M
    Am J Hematol; 2021 Jul; 96(7):790-795. PubMed ID: 33836555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues.
    Yu X; Munoz-Sagredo L; Streule K; Muschong P; Bayer E; Walter RJ; Gutjahr JC; Greil R; Concha ML; Müller-Tidow C; Hartmann TN; Orian-Rousseau V
    Blood; 2021 Sep; 138(12):1067-1080. PubMed ID: 34115113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia.
    Eide CA; Kurtz SE; Kaempf A; Long N; Agarwal A; Tognon CE; Mori M; Druker BJ; Chang BH; Danilov AV; Tyner JW
    Leukemia; 2020 Sep; 34(9):2342-2353. PubMed ID: 32094466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response.
    Sharon D; Cathelin S; Mirali S; Di Trani JM; Yanofsky DJ; Keon KA; Rubinstein JL; Schimmer AD; Ketela T; Chan SM
    Sci Transl Med; 2019 Oct; 11(516):. PubMed ID: 31666400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.